Nextrials and InClin Partner on Integrated Clinical Research Services
Nextrials, Inc.
, a provider of clinical research software and services, announced a partnership with
InClin
, a specialized clinical research organization (CRO) conducting Phase 1-4 studies for the pharmaceutical, biotechnology and medical device industries. With this partnership, researchers can take full advantage of each company’s strengths by linking Nextrials’
Prism
®, an award winning clinical trial data management platform, with InClin’s personalized, high-quality services to accelerate study starts and significantly lower drug development costs.
“Our companies have similar approaches to research, particularly when it comes to offering exceptional clinical trial performance and service,” said Dirk Thye, MD, CEO of InClin. “We take pride in our ability to deliver superior data quality to our sponsors, and Nextrials’ Prism meets our high standards as an enabling data management platform that can significantly shorten the length of time it takes to initiate and monitor a clinical trial. Together, we can help sponsors attain high quality data and potentially expedite the path to approval.”
Prism, its design tools and its new iPad interface give pharmaceutical and biotech researchers anytime/anywhere access to key data points, reports and statistics about ongoing studies, regardless of location. It enables sponsors to better manage investigator site data, logistics and costs, including access to real-time data related to patient demographics, recruitment/enrollment status, queries and more.
“As clinical trials become more complex, partnerships such as this one remove some of the organizational and integration headaches from study initiation and monitoring,” said James Rogers, CEO and co-founder of Nextrials. “Prism’s capabilities, combined with InClin’s senior project management team and its standardized performance indicators and quality metrics processes, give sponsors an edge in obtaining critical study data on a timely basis and keeping studies on track.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
